Trading Statement

RNS Number:0685M
Bespak PLC
10 May 2005

                                                                10 May 2005


                                   Bespak plc

              Trading update for the 52 weeks ended 30 April 2005



Bespak plc (LSE: BPK), a leader in specialty medical devices, today announces
that trading for the year is consistent with its expectations, with activity in
the second half weighted to the final months of the period. The transfer of
certain production from the Company's plant in Cary, North Carolina to the UK
proceeds as planned towards an anticipated shut-down in August 2005.



Looking ahead, two key issues will continue to influence our performance. In
March, the FDA announced that CFC albuterol formulations cannot be sold in the
US after December 2008, and US customers are now considering the impact of this
ruling. In February, Pfizer announced that it had filed the NDA for Exubera(R)
in the US, which followed the European filing in February 2004. We remain
confident in our continuing growth prospects, although we are cautious in the
near term in view of a stepped increase in pension costs.



Bespak will announce its full year results on 13 July 2005.


For further information please call:


Bespak plc
Mark Throdahl - Chief Executive                         [phone]
Martin Hopcroft - Group Finance Director

Buchanan Communications                                 [phone]
Tim Thompson / Mark Court



About Bespak plc

Bespak, a specialty medical devices company, is at the forefront of developing
new delivery systems for the pharmaceutical industry. The company has a product
range covering metered dose inhalers, dry powder devices, actuators and
compliance aids. The company also develops and manufactures drug delivery
devices for leading global pharmaceutical companies. The group, which has
facilities in King's Lynn and Milton Keynes in the UK and in Cary, North
Carolina, in the USA. is a public company quoted on the Official list of the
London Stock Exchange (LSE: BPK). For more information, please visit
www.bespak.com.






                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

TSTFGGGKVLKGKZM